From Diabetes to Degenerative Diseases: The Multifaceted Action of Metformin.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and therapeutic potential without systematic review methodology
PubMed 41097011 · doi:10.3390/ijms26199748
What was done
This narrative review synthesizes the established glucose-lowering mechanisms of metformin in type 2 diabetes mellitus and examines emerging evidence regarding its pleiotropic effects on cellular aging pathways and age-related degenerative conditions, including neurodegenerative disorders, cardiovascular diseases, age-related macular degeneration, and osteoporosis.
What was found
The abstract provides no quantitative data, effect sizes, or study counts. It describes key biological mechanisms involved in metformin's proposed broader effects, specifically AMPK activation, mTOR pathway modulation, reduction of oxidative stress, and promotion of autophagy.
Why it matters
It summarizes mechanistic rationales supporting the potential repurposing of metformin as an intervention targeting shared biological hallmarks of aging and chronic degenerative diseases.
Limits
As a narrative review, it presents no original primary experimental or clinical data and lacks a systematic search protocol or quantitative synthesis. Clinical efficacy, optimal dosing, and safety in non-diabetic populations for degenerative disease indications cannot be determined from the abstract.
Cited by
- context Metformin improves insulin sensitivity to clear glucose from the bloodstream into cells for energy.